Table 3 Demographic and clinical characteristics at baseline of persons with heart failure in the intervention and control groups (N = 60)
|  | Intervention (n = 30) Frequency (%) OR Mean (SD) | Control (n = 30) Frequency (%) OR Mean (SD) |
|---|---|---|
Age (in years) | 75.67 (7.45) | 75.75 (10.21) |
Gender | ||
 Men | 20 (66.67) | 22 (73.33) |
 Women | 10 (33.33) | 8 (26.67) |
Nationality | ||
 Swiss | 28 (93.33) | 27 (90.00) |
 Other European | 1 (3.33) | 2 (6.66) |
 Non-European | 1 (3.33) | 0 (0.00) |
Education (n = 57) | ||
 Obligatory school or less | 6 (20.00) | 7 (23.33) |
 Secondary school | 14 (46.67) | 10 (33.33) |
 Tertiary school | 8 (26.67) | 12 (40.00) |
Enough resources to pay for medications and health care services (n = 58) | ||
 Yes | 26 (86.67) | 26 (86.67) |
 No | 3 (10.00) | 3 (10.00) |
Life situation (n = 59) | ||
 Living alone | 9 (30.00) | 8 (26.67) |
 Living with someone | 21 (70.00) | 21 (70.00) |
Support person (n = 59) | ||
 Yes | 29 (96.67) | 28 (93.33) |
 No | 1 (3.33) | 1 (3.33) |
Post myocardial infarction | 9 (30.00) | 14 (46.67) |
Aetiology of heart failure | ||
 Ischaemic heart disease | 22 (73.33) | 20 (66.67) |
 Hypertension | 14 (46.67) | 15 (50.00) |
 Valvular heart disease | 12 (40.00) | 11 (36.67) |
 Arrythmia | 17 (56.67) | 16 (53.33) |
 Cardiomyopathy | 2 (6.67) | 3 (10.00) |
 Other | 2 (6.67) | 2 (6.67) |
Comorbidity | ||
 Diabetes | 10 (33.33) | 10 (33.33) |
 Hypertension | 19 (63.33) | 16 (53.33) |
 Cerebrovascular disease | 3 (10.00) | 9 (30.00) |
 Renal disease | 12 (40.00) | 21 (70.00) |
 Cancer | 8 (26.67) | 2 (6.67) |
 Depression/anxiety | 5 (16.67) | 9 (30.00) |
 Cognitive impairment | 1 (3.33) | 1 (3.33) |
 Charlson Comorbidity Index (%) | 5.97 (1.96) | 6.86 (1.75) |
NYHA (n = 59)a | ||
 II | 13 (43.33) | 8 (26.67) |
 III | 11 (36.67) | 13 (43.33) |
 IV | 6 (20.00) | 8 (26.67) |
Left ventricular ejection fraction (EF) (%) | 38.89 (15.59) | 36.06 (14.59) |
HFpEFa | 17 (60.71) | 20 (66.67) |
HFmrEFa | 2 (7.14) | 4 (13.33) |
HFrEFa | 9 (32.14) | 6 (20.00) |
Systolic BP (mmHg)a | 119.50 (17.61) | 115.87 (14.34) |
Treatment | ||
 Angiotensin-converting enzyme inhibitor (ACE-I) | 10 (33.33) | 6 (20.00) |
 Angiotensin II receptor blockers (ARB) | 7 (23.33) | 8 (26.66) |
 Beta-blocker | 27 (90.00) | 24 (80.00) |
 Diuretic | 27 (90.00) | 24 (80.00) |
 Digoxin/digitalis | 1 (3.33) | 0 (0.00) |
 Mineralocorticoid receptor antagonist (MRA) | 9 (30.00) | 10 (33.33) |
 Angiotensin receptor-neprilysin inhibitor (ARNI) (Entresto) | 6 (20.00) | 6 (20.00) |
 Anticoagulant | 13 (43.33) | 16 (53.33) |
 Calcium channel blocker (CCB) | 5 (16.66) | 6 (20.00) |
 Antihypertensive agents, vasodilators (Minoxidil) | 0 (0.00) | 1 (3.33) |
 Vasodilators (nitrates) | 1 (3.33) | 3 (10.00) |
 Coronary vasodilator | 0 (0.00) | 1 (3.33) |
 Antiarrhythmic (amiodarone) | 1 (3.33) | 3 (10.00) |
 Thiazide diuretic with potassium-sparing diuretic (comilorid) | 1 (3.33) | 0 (0.00) |
Sleep disturbance | ||
 Yes | 17 (56.67) | 14 (46.67) |
 No | 13 (43.33) | 16 (53.33) |
Daytime sleepiness | ||
 Yes | 6 (20.00) | 10 (34.48) |
 No | 24 (80.00) | 19 (65.52) |
LOS index hospitalization (days) | 17.83 (18.63) | 11.17 (7.38) |